ESMO 2023: Does stopping VEGFR TKI treatment and continuing immunotherapy influence the survival of patients on combination therapy?
In many countries, combinations of VEGFR TKI anti-cancer mediations plus [...]
ESMO 2023: A new immunotherapy, volrustomig, for the first-line treatment of advanced kidney cancer
Blocking the action of two proteins in cancer cells (PD-1 [...]
Patients with metastatic kidney cancer on immunotherapy may benefit from nephrectomy
Surgery to remove the kidney and tumour (nephrectomy) has an [...]
Pembrolizumab plus lenvatinib for non-clear cell kidney cancer
Immunotherapy combinations are becoming the standard treatment for people with [...]
Anticancer medication and risk of blood clots in hospitalised cancer patients with COVID-19
In this study, nearly 5,000 hospitalised cancer patients who were [...]
Belzutifan significantly delays progression of advanced kidney cancer after other treatments have failed
Kidney cancers often have mutations in a gene called the von Hippel-Lindau [...]
Corticosteroids during treatment with nivolumab may not affect survival in kidney cancer
A recent study published in the journal JAMA Oncology has [...]
Adjuvant therapy for kidney cancer
Adjuvant therapy aims to reduce the risk of the cancer [...]
Hormonal immune-related side effects to immunotherapies
This study looked at the incidence, diagnosis and treatment of [...]
Factors influencing kidney cancer outcomes with immunotherapy
This video interview discusses the effect of certain factors such [...]
